Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We have treated over 2,000 patients globally since the start of our first clinical trial and I'm very proud of this team's achievements and commitment to patients |
| Our KIMMTRAK sales and current cash put us in an excellent position to transform outcomes for patients by accelerating this portfolio with multiple clinical opportunities across three therapeutic areas |
| This is part of the reason why we're so excited about the PIWIL program and our mechanism, which is very distinct from checkpoints, where we don't need preexisting immunity or infiltration by the immune system into the tumor |
| In our second year of launch, 2023 has been an impressive year of KIMMTRAK sales, with net revenues growing to $67.6 million in Q4 from $62.6 million in Q3, primarily driven by the 13% growth in the United States |
| On a personal note, I am excited about our future because of this past year |
| We believe KIMMTRAK has significant potential for additional growth in the medium and long-term, driven by two registrational clinical trials |
| So when it comes to uveal melanoma, ctDNA, we have really strong confidence |
| And as we move forward into the next fiscal year, we remain steadfast in our mission to drive growth, create value and deliver results |
| This past year has been a testament to our drive to bring contract to patients, our innovation into bringing more novel targets and entering a new therapeutic area, and as always, our commitment to patients by working with sense of urgency |
| First, continued commercial growth driven by the U.S.; second, mid-term growth driven by Q4 data from TEBE-AM trial; and third, long-term growth with the ATOM trial expected to start recruiting this year |
| This is certainly an exciting and productive period at Immunocore as we continue to pioneer TCR bispecifics for cancer, for infectious diseases, and now for autoimmune diseases |
| This candidate has another exciting feature |
| So this is one of the reasons why we're excited about this program and its potential application in CRC |
| So, look, we've had a very successful set of years, a couple of years in Europe where we've launched in Germany, France, significantly, but as well as Italy and six other countries |
| And beyond 2024 in the mid-term, we're expecting, as David has mentioned, TEBE-AM study data, as well as in the long-term, the ATOM trial, which we're very excited about |
| So once we see the data, we hope that this is bringing significant value |
| I had the privilege to meet one of the first patients in our clinical trial, a parent of four that has been taking KIMMTRAK for seven years and is doing well |
| Our goal in 2024 is to continue our growth momentum in the United States and reach more patients globally, including our next country Spain |
| Reflecting now on the pipeline, Immunocore has an industry-leading bispecific TCR pipeline that now spans three therapeutic areas and reflects the large potential of our impacts platform |
| This growth was primarily driven by continued commercial progress in the United States |
| So, in closing, I would like to express really my gratitude to our patients, to our shareholders and to the team |
| Going into 2024, we see three growth opportunities |
| In 2023, we continue to advance our three strategic pillars of maximizing the potential of KIMMTRAK, advancing our clinical portfolio, and continuing to innovate for sustainable growth |
| Total sales for the year at $238 million were an increase of 70% over 2022 |
| Good morning and great update |
| In the fourth quarter, we reported $67.6 million in net revenues, which represents an 8% increase from the prior quarter |
| In reflecting our enthusiasm for the PRAME targets, we are advancing two new candidates into the clinic this year |
| We're also excited to potentially expand the benefit of KIMMTRAK through additional indications with our clinical program, which I will take you through in the next slide |
| We are pleased to have a clinical trial collaboration and nivolumab supply agreement with BMS for this trial |
| Ralph? Ralph Torbay So, Peter, we had a great 13% quarter-over-quarter growth in the U.S |
| Statement |
|---|
| sales were a little bit flat I would say |
| Two questions from us |
| Actual events may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those disclosed in our filings with the SEC |
| There is also an Fc fusion, which prolongs the half-life and enables less frequent dosing |
Please consider a small donation if you think this website provides you with relevant information